You need to be logged in to save products in your wishlist
Wester continued, Given that the metabolic syndrome is a major driver of liver-related outcomes both in patients with MASLD and other chronic liver diseases such as alcohol-related liver disease or viral hepatitis C, there could be a similar effect of GLP1 agonists in patients with chronic liver diseases of any etiology with concomitant metabolic traits, such as type 2 diabetes. Using data from the Decoding the Epidemiology of LIVER disease Swedish cohort, researchers aimed to determine the long-term risk for major adverse liver outcomes (MALO) among patients with chronic liver disease and type 2 diabetes who either initiated (n = 1,026) or did not initiate (n = 15,633) GLP1 agonists
However, these plans are not without their challenges
David Geier triple-board certified orthopedic surgeon, sports medicine specialist, and anti-aging and regenerative medicine expert
The efficacy of semaglutide in weight management has been demonstrated in numerous clinical trials, where participants receiving the medication showed greater weight loss compared to those on a placebo